Drug profile · INN
aliskiren hemifumarate
RASILAMLO
aliskiren hemifumarate (RASILAMLO) is a renin inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — aliskiren hemifumarate
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
aliskiren hemifumarate (RASILAMLO) is a renin inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Renin inhibitor
Primary target: Renin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is aliskiren hemifumarate?
aliskiren hemifumarate (RASILAMLO) is a renin inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for aliskiren hemifumarate?
RASILAMLO is a marketed brand name for aliskiren hemifumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aliskiren hemifumarate?
aliskiren hemifumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.